World Malaria Report 2019December 2019 read more
“The World malaria report 2019 provides a comprehensive update on global and regional malaria data and trends. The report tracks investments in malaria programmes and research as well as progress across all intervention areas: prevention, diagnosis, treatment, elimination and surveillance. It also includes dedicated chapters on the consequences of malaria on maternal, infant and child health, the “High Burden to High Impact” approach as well as biological threats to the fight against malaria.”
Power to the People
“The struggle to end the AIDS epidemic continues to be inextricably linked with the struggle to end
human rights violations, including discrimination and violence against women and girls and the
marginalization and criminalization of key populations—sex workers, people who use drugs, gay men
and other men who have sex with men, transgender people and prisoners.
This report argues that power in fact rests in the hands of the people, as can be seen in countless local, national and international movements to redistribute power and bring greater attention to neglected issues.”
42nd Global Fund Board Meeting Report
GFAN’s report on the 42nd Global Fund Board Meeting held in Geneva, Switzerland on 14-15 November 2019.
GFAN Guide to Global Fund Board Meetings
A short guide to Global Fund Board Meetings and the role that civil society has on the Board.
Policy Update: Lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis of active tuberculosis in people living with HIV
Publisher: World Health Organisation (WHO)
“The World Health Organization (WHO) has updated its guidance for the use of lateral flow urine lipoarabinomannan assay (LAM) in the diagnosis of tuberculosis (TB). Tests based on the detection of mycobacterial LAM antigen in urine have emerged as potential point-of-care tests for TB. The WHO Global TB Programme recommended the use of LF-LAM for the first time in 2015. Urinary LAM assays have shown greater sensitivity when used for the diagnosis of TB in people living with HIV. The sensitivity increases significantly in patients with lower CD4 cell counts. Following the new evidence, WHO is now recommending LF-LAM use to assist in diagnosis in a broader group of people, both in inpatient and outpatient settings.”
Source: Policy Update
Tuberculosis and Universal Health CoverageOctober 2019 read more
Publisher: Results UK
This report aims to define what provision of TB services in “the context of progress towards UHC” looks like in practice, and to what extent the recognition of the codependency of achieving TB and UHC at international fora like the UN and WHO translates to action at ground level. It defines an essential set of services that would both help to make the TB response “universal” and help to make the TB response contribute to the achievement of UHC more broadly.
GLOBAL PUBLIC INVESTMENT: Five paradigm shifts for a new era of aid
Publisher: JLI with Funding and support from ICSS, GFAN, PITCH-FSP and the Ministry of Foreign Affairs in the Netherlands.
“While there is much to applaud about development progress, there is also much of concern, not least with regard to widening inequality and threats to our environment. With the advent of the Sustainable Development Goals, however, there is a bold global framework through which to address common challenges and build a coherent response.
An area where thinking and practice in the international development sector will need to evolve is in its approach to “aid”. With worrying signs of growing nationalism in many countries, we need to strengthen our discourse of solidarity and shared responsibility. The changing nature of geopolitics is conducive to doing that as the voices of the Global South continue to strengthen in the international arena.
This is the context in which this report proposes a new vision for development co-operation. Building
on the best of “aid”, it suggests a series of paradigm shifts to modernise our approach. Those shifts
include raising ambitions from the level of the MDGs to that of the more comprehensive SDGs;
emphasising the unique value of concessional international public finance as a complement to
other sources of development finance; recognising the shifting geography of development co-operation
to which all the world’s countries now contribute one way or another, and suggesting governance
arrangements to reflect that. We should also insist on a new narrative to replace the old-fashioned and
misleading language of “donors” and “aid”. “
The Problem with Patents
Publisher: Frontline AIDS
The introduction of combination antiretroviral therapy (ART) in 1996 was one of the most significant interventions in the history of the HIV response. Combination therapy today means that in many parts of the world, AIDS is no longer seen as a death sentence. However, in the early days of the AIDS epidemic, very few people could access this treatment. People living with HIV led efforts across the world to improve access to treatment including campaigning to reduce the prices of HIV medicines. In 2018, over 23 million people were accessing ART but the struggle to ensure affordable access to treatment for all is not over.
Resurgence: Could AIDS, tuberculosis and malaria make comebacks?
The world has made remarkable progress over the past two decades to address AIDS, tuberculosis and malaria, and increased investment can help ensure disease resurgence does not undo these gains. Stepped-up funding for the Global Fund and U.S. bilateral programs is our best defense against future disease resurgence.
The path forward is clear: to end AIDS, tuberculosis and malaria, we must scale up prevention and treatment, strengthen surveillance systems and invest in innovation. Drawing on historical examples and empirical evidence about resurgence, this new report demonstrates why it is crucial for U.S. policymakers to invest in the Global Fund.
MAKING THE SWITCH: Saving More Lives with Optimal Treatment for Drug-Resistant TB
Publisher: MSF Access Campaign
Previously recommended treatment regimens for drug-resistant tuberculosis (DR-TB) used by most countries had a high pill burden, long treatment duration (of up to two years), painful daily injections (for up to eight months), severe side effects (due to toxic drugs) and poor treatment outcomes. These suboptimal regimens achieved treatment success rates of only 55% for people with multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) and 34% for people with extensively drug-resistant TB.
The World Health Organization (WHO) issued new MDR/RR-TB treatment guidelines in March 2019. This technical brief provides a summary of the treatment regimens now recommended by WHO, which represent hope for people with DR-TB and their caregivers because they offer better cure rates and fewer side effects using safer all-oral treatment.
Médecins Sans Frontières (MSF) urges countries to make a timely switch to these regimens given the clear benefits of providing bedaquiline for all people with MDR-TB and the urgent need to discontinue use of harmful injectable agents.